{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:11:54Z","timestamp":1790730714916,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K02537"],"award-info":[{"award-number":["25K02537"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K02395"],"award-info":[{"award-number":["24K02395"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22H02928"],"award-info":[{"award-number":["JP22H02928"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bmc.2026.118665","type":"journal-article","created":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T05:12:37Z","timestamp":1776575557000},"page":"118665","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Development and preclinical evaluation of [111In]In-DTPA-EphA2-57-1: a single-photon emission computed tomography probe targeting EphA2-expressing tumors"],"prefix":"10.1016","volume":"138","author":[{"given":"Minon","family":"Sasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Iwasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sato","family":"Oshige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Omokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2026.118665_bb0005","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.biocel.2008.07.019","article-title":"Eph\/ephrin signaling in epithelial development and homeostasis","volume":"41","author":"Miao","year":"2009","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.bmc.2026.118665_bb0010","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13045-020-00944-9","article-title":"Targeting EphA2 in cancer","volume":"13","author":"Xiao","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bmc.2026.118665_bb0015","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/135285","article-title":"Eph receptors and ephrin ligands: important players in angiogenesis and tumor angiogenesis","volume":"2010","author":"Mosch","year":"2010","journal-title":"J Oncol"},{"key":"10.1016\/j.bmc.2026.118665_bb0020","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1248\/bpb.b17-00446","article-title":"Emerging and diverse functions of the EphA2 noncanonical pathway in cancer progression","volume":"40","author":"Zhou","year":"2017","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.bmc.2026.118665_bb0025","first-page":"2301","article-title":"EphA2 overexpression causes tumorigenesis of mammary epithelial cells","volume":"61","author":"Zelinski","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2026.118665_bb0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1517\/14728222.2011.538682","article-title":"Emerging strategies for EphA2 receptor targeting for cancer therapeutics","volume":"15","author":"Tandon","year":"2011","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.bmc.2026.118665_bb0035","first-page":"613","article-title":"Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival","volume":"9","author":"Kinch","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2026.118665_bb0040","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1038\/sj.onc.1204004","article-title":"The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization","volume":"19","author":"Ogawa","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.bmc.2026.118665_bb0045","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.7150\/thno.72404","article-title":"Exosomal EPHA2 derived from highly metastatic breast cancer cells promotes angiogenesis and metastasis","volume":"12","author":"Han","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.bmc.2026.118665_bb0050","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12935-025-03826-7","article-title":"EphrinA2 promotes glioma cell migration and invasion through EphA2 and FAK","volume":"25","author":"Hirai","year":"2025","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.bmc.2026.118665_bb0055","article-title":"EPHA2 promotes triple negative breast cancer progression by suppressing pyroptosis via the AKT\/PI3K\/mTOR pathway","volume":"15","author":"Huang","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.bmc.2026.118665_bb0060","first-page":"253","article-title":"Cell division regulation by receptor tyrosine kinases","volume":"92","author":"Nakayama","year":"2020","journal-title":"J Biochem"},{"key":"10.1016\/j.bmc.2026.118665_bb0065","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ccr.2005.07.005","article-title":"A conditional feedback loop regulates Ras activity through EphA2","volume":"8","author":"Macrae","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bmc.2026.118665_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252212191","article-title":"EphA2 in cancer: molecular complexity and therapeutic opportunities","volume":"25","author":"Toracchio","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2026.118665_bb0075","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1038\/s41388-021-01714-8","article-title":"Oncogenic functions and therapeutic targeting of EphA2 in cancer","volume":"40","author":"Wilson","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.bmc.2026.118665_bb0080","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1158\/1535-7163.MCT-19-1092","article-title":"MMAE delivery using the bicycle toxin conjugate BT5528, a bicyclic peptide-based targeted cytotoxin for EphA2-expressing tumors","volume":"19","author":"Bennett","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2026.118665_bb0085","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/sj.bjc.6604676","article-title":"Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer","volume":"99","author":"Chang","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bmc.2026.118665_bb0090","first-page":"128","article-title":"Targeted delivery of paclitaxel to EphA2-expressing cancer cells using YSA peptide\u2013paclitaxel conjugates","volume":"19","author":"Wang","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2026.118665_bb0095","article-title":"EphA2-specific microvesicles derived from tumor cells facilitate the targeted delivery of chemotherapeutic drugs for osteosarcoma therapy","volume":"22","author":"Wang","year":"2024","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.bmc.2026.118665_bb0100","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1080\/15384047.2016.1235663","article-title":"Novel anti-EPHA2 antibody, DS-8895a for cancer treatment","volume":"17","author":"Hasegawa","year":"2016","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.bmc.2026.118665_bb0105","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s10637-022-01237-3","article-title":"A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2-positive cancers","volume":"40","author":"Gan","year":"2022","journal-title":"Investig New Drugs"},{"key":"10.1016\/j.bmc.2026.118665_bb0110","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10637-012-9801-2","article-title":"Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors","volume":"31","author":"Annunziata","year":"2013","journal-title":"Investig New Drugs"},{"key":"10.1016\/j.bmc.2026.118665_bb0115","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1200\/JCO.23.01107","article-title":"Results from first-in-human phase I dose-escalation study of a novel bicycle toxin conjugate targeting EphA2 (BT5528) in patients with advanced solid tumors","volume":"42","author":"Bashir","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmc.2026.118665_bb0120","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1007\/s00259-007-0503-5","article-title":"Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice","volume":"34","author":"Cai","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.bmc.2026.118665_bb0125","doi-asserted-by":"crossref","first-page":"974","DOI":"10.2967\/jnumed.115.169839","article-title":"Molecular imaging and quantitation of EphA2 expression in xenograft models with 89Zr-DS-8895a","volume":"57","author":"Burvenich","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bmc.2026.118665_bb0130","doi-asserted-by":"crossref","first-page":"7030","DOI":"10.1021\/acsomega.2c07849","article-title":"Novel [111In]in-BnDTPA-EphA2-230-1 antibody for single-photon emission computed tomography imaging tracer targeting of EphA2","volume":"8","author":"Furukawa","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.bmc.2026.118665_bb0135","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1007\/s00259-025-07139-9","article-title":"Theranostics using 89Zr\/177Lu labeled antibody targeting erythropoietin-producing hepatocellular receptor a2 (EphA2)","volume":"52","author":"Watabe","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.bmc.2026.118665_bb0140","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.3390\/diagnostics12123023","article-title":"Development of an in-house EphA2 ELISA for human serum and measurement of circulating EphA2 levels in hypertensive patients with renal dysfunction","volume":"12","author":"Murakoshi","year":"2022","journal-title":"Diagnostics"},{"key":"10.1016\/j.bmc.2026.118665_bb0145","first-page":"459","article-title":"Comparative study of 111In-labeled monoclonal antibodies using spacer-containing or non-spacer bifunctional chelating agents: labeling methods and in vitro stability","volume":"31","author":"Sun","year":"1994","journal-title":"Nucl Med"},{"key":"10.1016\/j.bmc.2026.118665_bb0150","article-title":"Anti-HER2 monoclonal antibody-based radioimmunoconjugates: assessment of the chelating agent influence","volume":"33","author":"Camargo Miranda","year":"2021","journal-title":"Bioorg Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626001215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626001215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:43:39Z","timestamp":1780101819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089626001215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":30,"alternative-id":["S0968089626001215"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118665","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and preclinical evaluation of [111In]In-DTPA-EphA2-57-1: a single-photon emission computed tomography probe targeting EphA2-expressing tumors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118665","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118665"}}